Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 13/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.60 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | TPO | P07202 | 1/20 | 0.48 |
| ▸ | EPX | P11678 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068099 | 0.86 | MGMT (0.76) | MGMTCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL6356857 | 0.82 | MGMT (0.69) | MGMTLMNAMAPT | |
| SCHEMBL5039831 | 0.80 | MGMT (0.65) | MGMTCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL8507246 | 0.79 | MGMT (0.65) | MGMTCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL311200 | 0.78 | MGMT (0.64) | MGMTCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL3305092 | 0.78 | PIN1 (0.71) | MGMTCCNA2CDK2CCNA1CDK1 | |
| Pyrimidine SCHEMBL6431067 | 0.77 | MGMT (0.63) | MGMTLMNAMAPT | |
| SCHEMBL3338311 | 0.77 | MGMT (0.68) | MGMTCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL8722332 | 0.77 | MGMT (0.63) | MGMTCCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL6358672 | 0.76 | MGMT (0.66) | MGMTCCNA2CDK2CCNA1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250135039-A1 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | FRED HUTCHINSON CANCER CENTER | 2025-05-01 | — | — | US | disclosed |
| EP-4476331-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240368582-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | ENSOMA, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4319773-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023150393-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-5916894-A | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| US-5753668-A | Substituted benzyloxypyrimidines and their inactivation of O6 -alkylguanine-DNA alkyltransferase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5525606-A | CHEMOTHERAPEUTIC ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGMT 6/4885CCNA2 830/4885CDK2 1566/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGMT 6/4885CCNA2 830/4885CDK2 1566/4885 |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | MGMT 1/4885CCNA2 265/4885CDK2 292/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | MGMT 1/4885CCNA2 259/4885CDK2 305/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MGMT 6/4885CCNA2 830/4885CDK2 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.